Javascript must be enabled to continue!
Abstract 316: Missing Data and the SOFA Score in Cardiac Arrest Research: A Scoping Review
View through CrossRef
Introduction:
The Sequential Organ Failure Assessment (SOFA) score is often used as an outcome or exposure in cardiac arrest studies. SOFA requires lab values and vital signs at certain time points which often results in missing data. How this missing data is handled is unknown.
Methods:
We performed a scoping review of PubMed, EMBASE, and Web of Science. English language peer-reviewed manuscripts were included. Titles/abstracts were screened by two independent reviewers to assess if they met inclusion criteria. Studies that met inclusion criteria were retrieved in full; those that did not were excluded. Disagreements between reviewers were resolved by a third reviewer.
Results:
The initial search provided 408 abstracts, 142 underwent full-text review (kappa: 0.91), and 66 were included (5 randomized controlled trials, 26 prospective and 25 retrospective studies). The studies had a median of 151 (IQR: 55, 278) subjects. SOFA was used as an outcome in 36 (55%) and a primary outcome in 10 (15%). Only 27 (41%) studies reported a method to handle missing SOFA data. The most common method was to exclude subjects with missing data (81%). Other methods were use of maximum SOFA while subjects were alive (11%), modified SOFA after excluding subjects who died prior to the timepoint (11%), and earlier and later SOFA to impute values (4%). When SOFA was the primary outcome, 4 (40%) reported a method; 3 (75%) excluded subjects and one (25%) used modified SOFA. Two studies conducted sensitivity analyses to test assumptions used to handle missing SOFA (one imputed values for death/discharge, one adjusted for mortality difference prior to SOFA measurement). Only 9 studies (14%) mentioned quantity of missing SOFA, ranging from 0-76% (median: 10% [IQR: 6%, 42%]). In the 50 studies using SOFA at time points after baseline, only 11 (22%) mentioned mortality prior to SOFA measurement; when mentioned, it ranged from 3%-76% with a median of 12% (IQR: 6%-35%).
Conclusion:
Missing data for SOFA scores used in cardiac arrest studies is pervasive yet often not acknowledged and/or handled with described or consistent methods. These findings illustrate that studies using SOFA may exhibit substantial bias and results could be misinterpreted, particularly if patients with missing data are excluded.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 316: Missing Data and the SOFA Score in Cardiac Arrest Research: A Scoping Review
Description:
Introduction:
The Sequential Organ Failure Assessment (SOFA) score is often used as an outcome or exposure in cardiac arrest studies.
SOFA requires lab values and vital signs at certain time points which often results in missing data.
How this missing data is handled is unknown.
Methods:
We performed a scoping review of PubMed, EMBASE, and Web of Science.
English language peer-reviewed manuscripts were included.
Titles/abstracts were screened by two independent reviewers to assess if they met inclusion criteria.
Studies that met inclusion criteria were retrieved in full; those that did not were excluded.
Disagreements between reviewers were resolved by a third reviewer.
Results:
The initial search provided 408 abstracts, 142 underwent full-text review (kappa: 0.
91), and 66 were included (5 randomized controlled trials, 26 prospective and 25 retrospective studies).
The studies had a median of 151 (IQR: 55, 278) subjects.
SOFA was used as an outcome in 36 (55%) and a primary outcome in 10 (15%).
Only 27 (41%) studies reported a method to handle missing SOFA data.
The most common method was to exclude subjects with missing data (81%).
Other methods were use of maximum SOFA while subjects were alive (11%), modified SOFA after excluding subjects who died prior to the timepoint (11%), and earlier and later SOFA to impute values (4%).
When SOFA was the primary outcome, 4 (40%) reported a method; 3 (75%) excluded subjects and one (25%) used modified SOFA.
Two studies conducted sensitivity analyses to test assumptions used to handle missing SOFA (one imputed values for death/discharge, one adjusted for mortality difference prior to SOFA measurement).
Only 9 studies (14%) mentioned quantity of missing SOFA, ranging from 0-76% (median: 10% [IQR: 6%, 42%]).
In the 50 studies using SOFA at time points after baseline, only 11 (22%) mentioned mortality prior to SOFA measurement; when mentioned, it ranged from 3%-76% with a median of 12% (IQR: 6%-35%).
Conclusion:
Missing data for SOFA scores used in cardiac arrest studies is pervasive yet often not acknowledged and/or handled with described or consistent methods.
These findings illustrate that studies using SOFA may exhibit substantial bias and results could be misinterpreted, particularly if patients with missing data are excluded.
Related Results
Patient-level reclassification and discordance between SOFA and SOFA-2: a multicenter ICU study
Patient-level reclassification and discordance between SOFA and SOFA-2: a multicenter ICU study
Abstract
Background
The Sequential Organ Failure Assessment (SOFA) score is widely used to quantify organ dysfunction in ...
Does SOFA-2 Improve Mortality Prediction in Sepsis? A Retrospective Single-Center Observational Cohort Study Comparing SOFA-1 and SOFA-2
Does SOFA-2 Improve Mortality Prediction in Sepsis? A Retrospective Single-Center Observational Cohort Study Comparing SOFA-1 and SOFA-2
Abstract
Background:
The Sequential Organ Failure Assessment (SOFA) score has been wide...
Does SOFA-2 improve mortality prediction in sepsis? A retrospective single-center observational cohort study comparing SOFA-1 and SOFA-2
Does SOFA-2 improve mortality prediction in sepsis? A retrospective single-center observational cohort study comparing SOFA-1 and SOFA-2
Abstract
Background
The Sequential Organ Failure Assessment (SOFA) score has been widely used for nearly three decades to...
SOFA-2 versus SOFA for mortality risk assessment in ICU patients with acute cholangitis: a retrospective cohort study using MIMIC-IV and eICU
SOFA-2 versus SOFA for mortality risk assessment in ICU patients with acute cholangitis: a retrospective cohort study using MIMIC-IV and eICU
Abstract
Background
Acute cholangitis (AC) can progress rapidly to organ failure and death. The Sequential Organ Failure Assessment-2 (SOFA-2) is a recently revise...
“ASSESSMENT OF SOFA VS QSOFA VS DELTA SOFA IN ICU PATIENTS”
“ASSESSMENT OF SOFA VS QSOFA VS DELTA SOFA IN ICU PATIENTS”
Objective: Ÿ To study the demographic prole of patients with sepsis and multiple organ dysfunction syndrome in patients with intensive care units. Ÿ To evaluate the use of SOFA Sc...
SOFA-2 Versus SOFA-1 for Mortality Prediction in Infection-Triggered ICU Patients
SOFA-2 Versus SOFA-1 for Mortality Prediction in Infection-Triggered ICU Patients
Background
Accurate assessment of organ dysfunction is essential for risk stratification in critically ill patients. The traditional Sequential Organ Failure As...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...

